VIVUS, Inc. is a specialty pharmaceutical company engaged in the development of innovative therapies for the treatment of quality-of-life disorders in men and women, with a focus on sexual dysfunction. The Company developed and markets in the U.S. MUSE(R)(alprostadil) and ACTIS(R) (recently cleared for OTC marketing), two innovations in the treatment of erectile dysfunction, and has
partnered with Abbott Laboratories (NYSE: ABT) for the international marketing and distribution of its male transurethral ED products. In Canada, VIVUS has partnered exclusively with Paladin Labs to market and distribute MUSE . VIVUS initiated clinical studies for its female
sexual dysfunction product, ALISTA(TM), during the fourth quarter of 2000.
Note to editors and investors: Additional written materials,recent releases and Company information are available through a variety of sources, including the VIVUS home page (www.vivus.com) and the VIVUS Fax-On-Demand Service (1-888-329-5719).
CONTACT: VIVUS, Inc.
Dick Walliser
650/934-5264
ir@vivus.com
www.vivus.com
or
INVESTOR CONTACTS:
Lippert/Heilshorn & Associates, Inc.
Bruce Voss (bruce@lhai.com)
Bonnie Feldman (bonnie@lhai.com)
310/691-7100
Media Contact
Pamela Rigler (pamela@lhai.com)
Carrie Kocik (carrie@lhai.com)
212/838-3777
www.lhai.com |
